Latest Period
Q1 2026
Security Snapshot
LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) Institutional Ownership
CUSIP: 528872302
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026
Institutions Reporting
133
Shares (Excl. Options)
323,297,986
Price
$1.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- LXRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 323,297,986
- Total 13F value
- $504,337,136
- Portfolio coverage rank
- 0%
- Share change
- +62,911,525
- Value change
- +$98,507,875
- Number of holders
- 133
- Shares outstanding
- 444,558,533
- SEC-reported price per share
- $2.41
- Insider filing price
- $2.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 528872302.
- 133 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 122 to 133 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $299,475,172 to $504,337,136.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 133 institutions filings for Q1 2026.
Security key
528872302
Latest holder period
Q1 2026
13F holders
133
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
LXRX full holder history
LEXICON PHARMACEUTICALS, INC. SEC filings
LEXICON PHARMACEUTICALS, INC. company facts
LEXICON PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 528872302:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
LXRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Invus Global Management, LLC | 39% | +8.9% | $273,243,457 | +$31,857,907 | 175,156,062 | +13% | Artal Participations S.a r.l. | 30 Apr 2026 |
| FMR LLC | 10% | +9% | $26,696,274 | +$2,516,037 | 38,137,535 | +10% | FMR LLC | 30 Jun 2025 |
As of 31 Mar 2026, 133 institutional investors reported holding 323,297,986 shares of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX). This represents 73% of the company’s total 444,558,533 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
71%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Artal Group S.A. | 35% | 154,734,327 | +14% | 24% | $241,385,550 |
| FMR LLC | 10% | 45,056,338 | +19% | 0% | $70,287,887 |
| Siren, L.L.C. | 10% | 44,303,518 | +14% | 1.9% | $69,113,488 |
| Sessa Capital IM, L.P. | 4% | 17,912,961 | +497% | 0.53% | $27,944,219 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1% | 9,519,167 | 0% | 0% | $14,849,901 |
| Point72 Asset Management, L.P. | 1.8% | 7,814,606 | +2651% | 0.02% | $12,190,785 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 4,944,731 | +2.6% | 0.01% | $7,713,780 |
| BlackRock, Inc. | 0.75% | 3,322,219 | +4.1% | 0% | $5,182,662 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.71% | 3,169,111 | +27% | 0% | $4,945,786 |
| JANE STREET GROUP, LLC | 0.6% | 2,665,938 | +55% | 0% | $4,158,863 |
| UBS Group AG | 0.56% | 2,483,182 | -17% | 0% | $3,873,764 |
| MARSHALL WACE, LLP | 0.53% | 2,376,304 | +88% | 0% | $3,707,035 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.48% | 2,121,164 | +76% | 0% | $3,309,016 |
| CIBC Bancorp USA Inc. | 0.4% | 1,800,000 | 0% | $2,808,000 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.36% | 1,600,500 | +508% | 0% | $2,496,780 |
| VANGUARD FIDUCIARY TRUST CO | 0.3% | 1,332,284 | 0% | 0% | $2,078,363 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.29% | 1,311,298 | +24% | 0% | $2,045,625 |
| TWO SIGMA INVESTMENTS, LP | 0.27% | 1,199,632 | +88% | 0% | $1,871,426 |
| CITADEL ADVISORS LLC | 0.25% | 1,094,901 | -36% | 0% | $1,708,045 |
| GOLDMAN SACHS GROUP INC | 0.24% | 1,070,517 | +16% | 0% | $1,670,007 |
| STATE STREET CORP | 0.22% | 964,038 | +9% | 0% | $1,503,899 |
| GSA CAPITAL PARTNERS LLP | 0.21% | 930,089 | -6.6% | 0.09% | $1,451,000 |
| Ishara Investments LP | 0.2% | 902,000 | +2.5% | 1.4% | $1,407,120 |
| Hennion & Walsh Asset Management, Inc. | 0.19% | 848,138 | -5.9% | 0.04% | $1,323,095 |
| MACKENZIE FINANCIAL CORP | 0.17% | 772,677 | 0% | $1,205,376 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
44
Latest
Q1 2026
Rows shown
1-25 of 44
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 323,297,986 | $504,337,136 | +$98,507,875 | $1.56 | 133 |
| 2025 Q4 | 260,415,048 | $299,475,172 | +$5,061,660 | $1.15 | 122 |
| 2025 Q3 | 255,139,258 | $344,428,817 | -$1,045,992 | $1.35 | 121 |
| 2025 Q2 | 256,310,843 | $242,983,204 | -$6,845,383 | $0.95 | 121 |
| 2025 Q1 | 265,818,368 | $122,485,430 | -$18,132,306 | $0.46 | 124 |
| 2024 Q4 | 297,662,439 | $220,126,714 | -$8,084,075 | $0.74 | 124 |
| 2024 Q3 | 288,616,985 | $453,067,592 | -$48,604,221 | $1.57 | 134 |
| 2024 Q2 | 278,343,151 | $467,625,172 | +$175,856,984 | $1.68 | 121 |
| 2024 Q1 | 171,815,966 | $412,351,239 | -$24,970,122 | $2.40 | 114 |
| 2023 Q4 | 182,858,180 | $279,771,925 | -$6,759,847 | $1.53 | 103 |
| 2023 Q3 | 188,793,708 | $205,786,015 | -$5,677,228 | $1.09 | 109 |
| 2023 Q2 | 191,326,157 | $438,152,499 | +$104,558,326 | $2.29 | 121 |
| 2023 Q1 | 145,600,839 | $353,808,486 | -$2,997,119 | $2.43 | 102 |
| 2022 Q4 | 146,885,188 | $280,547,551 | -$3,977,447 | $1.91 | 100 |
| 2022 Q3 | 148,905,062 | $357,360,311 | +$72,603,615 | $2.40 | 98 |
| 2022 Q2 | 118,779,098 | $220,940,693 | -$2,430,736 | $1.86 | 82 |
| 2022 Q1 | 120,193,264 | $251,304,091 | -$5,565,361 | $2.09 | 100 |
| 2021 Q4 | 121,559,642 | $478,894,149 | -$1,466,109 | $3.94 | 108 |
| 2021 Q3 | 121,205,281 | $583,005,732 | +$17,343,707 | $4.81 | 96 |
| 2021 Q2 | 117,708,489 | $540,207,653 | +$2,119,118 | $4.59 | 105 |
| 2021 Q1 | 121,214,904 | $711,532,085 | +$117,190 | $5.87 | 103 |
| 2020 Q4 | 122,029,255 | $417,334,864 | +$65,690,726 | $3.42 | 100 |
| 2020 Q3 | 104,248,250 | $150,106,719 | -$5,093,677 | $1.44 | 83 |
| 2020 Q2 | 107,177,053 | $213,813,923 | +$4,797,305 | $1.99 | 99 |
| 2020 Q1 | 104,815,254 | $204,388,139 | -$17,170,082 | $1.95 | 107 |